Milestone reports Q4 2024 net loss $12.4M; FDA PDUFA date for CARDAMYST is March 27, 2025

Milestone Pharmaceuticals Inc.

FDA PDUFA goal date for CARDAMYST (etripamil) in PSVT is March 27, 2025; launch targeted for mid-2025 if approved.
Cash, cash equivalents, and short-term investments: $69.7M as of Dec 31, 2024, vs $66.0M year-end 2023.
Q4 2024 net loss $12.4M ($0.19/share), improved from $13.6M ($0.32/share) in Q4 2023.
Full year 2024 net loss $41.5M ($0.67/share), vs $59.7M ($1.39/share) in 2023; revenue zero.
Phase 3 trial for etripamil in AFib-RVR on track to initiate in 2025 with patient self-administration regimen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.